The comparison between DEGs of HER2+ BC vs. normal samples revealed a group of differentially expressed pathways (Figure 3A) that consists of 13 pathways that were best able to classify HER2+ BC vs. normal samples. The gene discussed is ERBB2; the disease is breast cancer.